Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Prudence A. Francis(Peter MacCallum Cancer Centre), Meredith M. Regan(Dana-Farber Cancer Institute), Robert L. Coleman(Texas Oncology), Fabio Puglisi(University of Udine), Lorenzo Pavesi(University of Trento), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Barbara Ruepp(The Coordinating Center), Barbara Walley, Richard D. Gelber(Harvard University), Nancy E. Davidson(WinnMed), Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Rudolf Maibach(The Coordinating Center), Henry Gómez(National Cancer Center), Stefan Buchholz(University Hospital Regensburg), Marco Colleoni(European Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), Vered Stearns(Johns Hopkins University), Hervé Bonnefoi, Charles E. Geyer(Magee-Womens Hospital), Manuela Rabaglio(University Hospital of Bern), Simon Spazzapan(Centro di Riferimento Oncologico), Eric P. Winer(University of Vermont), Olivia Pagani(Swiss Group For Clinical Cancer Research), Alan S. Coates(International Breast Cancer Study Group), Eva Ciruelos(Hospital Universitario 12 De Octubre), James N. Ingle(Mayo Clinic), Marc Debled(Université de Bordeaux), István Láng(National Institute of Oncology), Miguel Ángel Climent(Radboud University Nijmegen), Angelo Di Leo(Hospital of Prato), Graziella Pinotti(Medica (Italy)), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Thomas Ruhstaller(University Hospital Bonn), Silvana Martino(Angeles Clinic and Research Institute), Matthew P. Goetz(Mayo Clinic)
Cited by 684
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k